Adefovir Dipivoxil (Adefovir Dipivoxil) Patent Expiration, LOE Window & CMS Spending

Adefovir Dipivoxil (Adefovir Dipivoxil) by Sigmapharm Labo: Multi-Source Generic Molecule, 2 AB generics, $2.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSigmapharm Labo
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$2.8M
2024 Medicare Part D Spend$2.3M
2024 Medicaid Spend$532K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel